Alnylam pharmaceuticals and medison pharma announce the expansion of their collaboration to a multi-regional partnership to commercialize rnai therapeutics

Zug, switzerland , march 9, 2023 /prnewswire/ --  alnylam pharmaceuticals, inc.  (nasdaq: alny), the leading rnai therapeutics company, and medison pharma ("medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes poland, czech republic, hungary, slovakia, lithuania, estonia and latvia, in addition to israel.  this new agreement builds upon the successful long-term partnership between alnylam and medison in israel and will allow alnylam to utilize medison's unique multi-regional platform to ensure that alnylam's innovative rna interference (rnai) therapeutics, such as onpattro® (patisiran), givlaari® (givosiran), and oxlumo® (lumasiran) are made available across additional countries in europe.
ALNY Ratings Summary
ALNY Quant Ranking